Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04024813
Other study ID # CB8025-21845
Secondary ID 2019-001760-30
Status Completed
Phase Phase 2
First received
Last updated
Start date November 12, 2019
Est. completion date January 9, 2020

Study information

Verified date June 2021
Source CymaBay Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date January 9, 2020
Est. primary completion date January 9, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Confirmed diagnosis of PSC based on any two of the following three criteria: - Historical evidence of an elevated AP > ULN from any prior laboratory result - Liver biopsy consistent with PSC - Abnormal cholangiography consistent with PSC as measured by MRCP, ERCP, or percutaneous transhepatic cholangiography (PTC) 2. Subjects must have the following specific additional laboratory parameters measured by the Central Laboratory at Screening: - AP = 1.5 × ULN and < 8 × ULN - Total bilirubin = 2 × ULN - ALT and AST = 5 × ULN - eGFR > 60 mL/min/1.73 m^2 - Platelets = 140 × 10^3/µL - International Normalized Ratio (INR) = 1.3 (in the absence of warfarin or other anticoagulant therapy) - Albumin = 3.5 g/dL 3. Patients taking UDCA will be allowed to enroll if meeting the following criteria: - Total daily dose of = 20 mg/kg/day - A minimum of 6 months of stable treatment - Minimum of 12 weeks off treatment prior to Screening if UDCA is recently discontinued Key Exclusion Criteria: 1. Clinically significant acute or chronic liver disease of an etiology other than PSC 2. Patients with a diagnosis of overlapping autoimmune hepatitis (AIH) and PSC 3. Secondary or IgG4 related sclerosing cholangitis 4. Small duct PSC 5. Presence of a cholangiocarcinoma on cholangiography or MRI at Screening as determined by the central radiologist and the principal investigator (PI) or medical monitor 6. Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation procedure of a stricture within 12 weeks of Screening 7. History, evidence, or high suspicion of cholangiocarcinoma or other hepatobiliary malignancy based on imaging, screening laboratory values, and/or clinical symptoms 8. Presumptive or diagnosed acute cholangitis within 12 weeks of Screening and through Day 1 9. Evidence of compensated or decompensated cirrhosis based on histology, relevant medical complications, or laboratory parameters: - Historical liver biopsy demonstrating cirrhosis (eg, Ludwig Stage 4 or Ishak Stage 5) - Current or prior history of decompensated liver disease, including ascites, hepatic encephalopathy, variceal bleeding or other clinical conditions consistent with cirrhosis and/or portal hypertension, - Liver stiffness > 14.4 kPa by FibroScan, or - Combined low platelet count (< 140 × 10^3/µL ) with one of the following: - Serum albumin < 3.5 g/dL, - INR > 1.3 (not due to antithrombotic agent use), or - Total bilirubin > ULN 10. Prior or actively listed for liver transplantation 11. Prior exposure to seladelpar Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Intervention

Drug:
Seladelpar
Capsule(s) administered orally once daily
Placebo to match Seladelpar
Capsule(s) administered orally once daily

Locations

Country Name City State
Canada Toronto Centre for Liver Disease-Toronto General Hospital Toronto Ontario
Poland ID Clinic Myslowice
United States Piedmont Atlanta Hospital Atlanta Georgia
United States University of Colorado Denver and Hospital Aurora Colorado
United States Schiff Center for Liver Diseases/University of Miami Miami Florida
United States New York University New York New York
United States Liver Institute of Virginia Newport News Virginia
United States Henry Ford Health System Novi Michigan
United States Bon Secours Liver Institute of Richmond Richmond Virginia
United States Sutter Pacific Medical Foundation - California Pacific Medical Center San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
CymaBay Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative change in Baseline serum alkaline phosphatase (AP) at Week 24 24 weeks
Secondary Incidence of treatment-emergent adverse events (TEAEs), as well as biochemistry, hematology, and urinalysis Up to 24 weeks
Secondary Incidence and severity of PSC-related symptoms or procedures Up to 24 weeks
Secondary Incidence of Hepatic disease progression events, defined by the occurrence of liver transplantation, MELD score, hepatic decompensation events, and/or hepatocellular carcinoma Up to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2
Withdrawn NCT03216876 - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Phase 1
Recruiting NCT02605213 - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Phase 4
Recruiting NCT01688024 - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT03041662 - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed NCT05866809 - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis Phase 2
Recruiting NCT05618145 - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT02247934 - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) N/A
Terminated NCT01142323 - Pilot Study of Fenofibrate for PSC Phase 1/Phase 2
Completed NCT01088607 - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Phase 1
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Recruiting NCT04133792 - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) Phase 3
Active, not recruiting NCT04595825 - CM-101 in PSC Patients -The SPRING Study Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Completed NCT02943460 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Phase 2
Completed NCT00951327 - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) N/A
Recruiting NCT05912387 - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Early Phase 1
Completed NCT02884557 - NKT Role in the Regulation of the Inflammatory Bowel Disease N/A
Recruiting NCT01398917 - Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Phase 3